Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.38 |
| ▸ | KDM5A | P29375 | 2/20 | 0.38 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.36 |
| ▸ | RET | P07949 | 4/20 | 0.35 |
| ▸ | SRC | P12931 | 3/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | ABL2 | P42684 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.33 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16611022 | 0.99 | LRRK2 (0.38) | LRRK2KDM5ABMPR1AACVRL1ACVR1 | |
| SCHEMBL16611724 | 0.91 | RET (0.40) | BMPR1AACVRL1ACVR1RETCHEK1 | |
| SCHEMBL16611003 | 0.86 | PIK3CG (0.36) | RETSRCABL1EGFRABL2 | |
| SCHEMBL16611226 | 0.85 | SRC (0.44) | SRCABL1EGFRABL2 | |
| SCHEMBL16611024 | 0.85 | KDM5A (0.36) | LRRK2KDM5ARETSRCABL1 | |
| SCHEMBL16610728 | 0.84 | ROCK2 (0.35) | SRCABL1EGFRABL2 | |
| SCHEMBL16610877 | 0.84 | SRC (0.46) | RETSRCABL1EGFRABL2 | |
| SCHEMBL16611505 | 0.83 | SRC (0.39) | RETSRCABL1EGFRABL2 | |
| SCHEMBL16610920 | 0.82 | ABL1 (0.35) | RETSRCABL1EGFRABL2 | |
| SCHEMBL16610732 | 0.81 | SRC (0.39) | RETSRCABL1EGFRABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | LRRK2 1393/4885KDM5A 132/4885BMPR1A 2893/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | LRRK2 1393/4885KDM5A 132/4885BMPR1A 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.